Equity strategies

Carmignac Portfolio Grande Europe

Luxembourg SICAV sub-fundEuropean marketSRI Fund Article 9
Share Class

LU0099161993

A high conviction, sustainable European equity strategy
  • Rigorous stock screening combined with bottom-up fundamental analysis form the bedrock of the investment process.
  • On the lookout for long-term growth, built on robust fundamentals and strong business models.
Asset Allocation
Equities97.1 %
Other2.9 %
Data as of:  31 Dec 2024.
Risk Indicator
4/7
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
+ 249.6 %
+ 104.0 %
+ 43.3 %
+ 8.6 %
+ 15.3 %
From 02/07/1999
To 09/01/2025
Calendar Year Performance 2024
- 1.4 %
+ 5.1 %
+ 10.4 %
- 9.6 %
+ 34.8 %
+ 14.5 %
+ 21.7 %
- 21.1 %
+ 14.8 %
+ 11.3 %
Net Asset Value
349.57 €
Asset Under Management
810 M €
Market
European market
SFDR - Fund Classification

Article

9
Data as of:  9 Jan 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.Until 31 December 2024, the Fund's reference indicator is Stoxx Europe 600 NR index. Performances are presented using the chaining method.

Carmignac Portfolio Grande Europe fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  31 Dec 2024.
Fund management team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager

Market environment

  • In December, Europe traded down around 0.5% for the month, with most of this decline occurring towards the end due to a hawkish Fed outlook for 2025, which impacted markets.
  • Europe’s largest company, Novo Nordisk, also disappointed the market towards the end of the month, further affecting the wider market.
  • The optimism generated in November by Trump's victory in the US elections has faded, with investors turning their attention to the impact of possible US tariffs and to the question of whether the Franco-German motor of the European Union will stall.

Performance commentary

  • During the month of December, the Fund recorded a slightly negative absolute performance, above its reference indicator.
  • Hermes has been the fund's top performer this month, driven by sell-side analysts' positive outlook on its resilient business model and high brand desirability.
  • Galderma, a recent addition to our portfolio, has also contributed to the Fund's performance. The company is poised to benefit from the early success of its newly approved atopic dermatitis treatment in the US.
  • Our biggest detractors this month has been Novo Nordisk whose shares experienced a significant decline on December 20th following disappointing results from tests of its latest obesity drug, CagriSema.
  • Despite this setback, CagriSema remains a valuable addition to Novo Nordisk's obesity product range and competes directly with Eli Lilly’s Zepbound
  • Having no exposure to Communication Services and Energy sectors has been supportive during the month.

Outlook strategy

  • During the month, our portfolio remained relatively stable without any major changes.
  • We decided to take some profits in a few names that have performed well recently, particularly our Financials holdings such as Euronext and Deutsche Borse.
  • On the other hand, we took advantage of the significant drop to increase our position in Novo Nordisk as our conviction didn’t significantly change.
  • The Fund continues to rely on bottom-up fundamental analysis with a medium-long term horizon.
  • We stick to our process of focusing on profitable companies with high returns on capital, reinvesting for growth and maintain our focus on stocks and sectors with strong visibility on sales and profits.

Performance Overview

Data as of:  9 Jan 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.Until 31 December 2024, the Fund's reference indicator is Stoxx Europe 600 NR index. Performances are presented using the chaining method.​From 01/01/2013 the equity index reference indicators are calculated net dividends reinvested. The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
Source: Carmignac at 10/01/2025

Carmignac Portfolio Grande Europe Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  31 Dec 2024.
Europe100.0 %
Total % Equities100.0 %
Europe100.0 %
frFrance
25.0 %
deGermany
22.7 %
chSwitzerland
13.7 %
nlNetherlands
13.3 %
dkDenmark
12.9 %
seSweden
5.4 %
ieIreland
3.4 %
esSpain
1.9 %
itItaly
1.7 %

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  31 Dec 2024.
Equity Investment Weight97.1 %
Net Equity Exposure97.1 %
Number of Equity Issuers35
Active Share83.4 %

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Manager.
Fund Management Team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
In our approach to European equities, we focus on sustainable high-quality companies which demonstrate high levels of profitability while favouring profits reinvestment over profits distribution to grow the business for the future.
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
View Fund's characteristics

Related articles

Sustainable investing10 July 2024English

Carmignac’s Article 9 funds: a sustainable investment?

3 minute(s) read
Find out more
Until 31 December 2024, the Fund's reference indicator is Stoxx Europe 600 NR index. Performances are presented using the chaining method.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.